EGFR and colorectal carcinoma: For instance, CRC patients with a low proportion of KRAS mutations shall be more likely to benefit from epidermal growth factor receptor (EGFR) antibody therapy (5), while patients with MSI-H molecular profiles do not receive an overall survival advantage from immune checkpoint-blockade administration (6).